| Title |
A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma
|
|---|---|
| Published in |
Targeted Oncology, July 2013
|
| DOI | 10.1007/s11523-013-0290-9 |
| Pubmed ID | |
| Authors |
Nate N. Waldron, Sanford H. Barsky, Phillip R. Dougherty, Daniel A. Vallera |
| Abstract |
The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of cells. Here, we characterized a bispecific targeted toxin that is composed of two antibody fragments and a catalytic protein toxin allowing it to bind two CSC markers on the same cell killing this resistant subpopulation. CD133 is a well-known CSC marker and has been successfully targeted and caused regression of head and neck squamous cell carcinoma (HNSCC) in vivo. To enable it to bind a broader range of CSCs, an anti-epithelial cell adhesion molecule (EpCAM) scFv was added to create dEpCAMCD133KDEL, a deimmunized bispecific targeted toxin on a single amino acid chain. This bispecific potently inhibited protein translation and proliferation in vitro in three different types of carcinoma. Furthermore, in a CSC spheroid model dEpCAMCD133KDEL eliminated Mary-X spheroids, an inflammatory breast carcinoma. Finally, this bispecific also caused tumor regression in an in vivo model of HNSCC. This represents the first bispecific CSC-targeted toxin and warrants further development as a possible therapy for carcinoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 23% |
| Other | 5 | 14% |
| Researcher | 5 | 14% |
| Student > Master | 5 | 14% |
| Student > Bachelor | 3 | 9% |
| Other | 2 | 6% |
| Unknown | 7 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 8 | 23% |
| Medicine and Dentistry | 7 | 20% |
| Biochemistry, Genetics and Molecular Biology | 5 | 14% |
| Chemistry | 2 | 6% |
| Immunology and Microbiology | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 9 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 August 2013.
All research outputs
#19,015,492
of 23,577,654 outputs
Outputs from Targeted Oncology
#402
of 567 outputs
Outputs of similar age
#150,224
of 199,657 outputs
Outputs of similar age from Targeted Oncology
#4
of 6 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 567 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,657 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.